This is a preview of subscription content, log in via an institution to check access.
Notes
2017 US dollars
Reference
Sarkar RR, et al. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute : 14 Dec 2018. Available from: URL: http://doi.org/10.1093/jnci/djy193
Rights and permissions
About this article
Cite this article
CAR-T cell therapy cost effective for paediatric B-cell ALL?. PharmacoEcon Outcomes News 819, 13 (2019). https://doi.org/10.1007/s40274-019-5552-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5552-z